Published in Semin Nucl Med on July 01, 2004
False-positive FDG PET uptake--the role of PET/CT. Eur Radiol (2005) 1.97
Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci (2006) 1.18
Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging (2006) 1.10
Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer. Eur J Nucl Med Mol Imaging (2007) 0.96
Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. J Cancer Res Clin Oncol (2011) 0.95
Clinical review: surgical management of locally advanced and recurrent colorectal cancer. Langenbecks Arch Surg (2013) 0.84
A comparison of positron emission tomography and colonoscopy for the detection of advanced colorectal neoplasms in subjects undergoing a health check-up. PLoS One (2013) 0.82
FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging (2009) 0.82
FDG-PET in colorectal cancer. Cancer Imaging (2006) 0.82
Diagnostic performance of ¹⁸F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with ¹⁸F-fluorodeoxyglucose PET/CT. Eur J Nucl Med Mol Imaging (2013) 0.79
Relationship between Preoperative ¹⁸F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Status in Primary Colorectal Cancer. Yonsei Med J (2016) 0.78
Impact of (18)F-FDG-PET/CT on staging and irradiation of patients with locally advanced rectal cancer. Strahlenther Onkol (2009) 0.77
Positron emission tomography for staging and assessment of tumor response of hepatic malignancies. Semin Intervent Radiol (2006) 0.77
Clinical application of multimodality imaging in radiotherapy treatment planning for rectal cancer. Cancer Imaging (2013) 0.75
FDG uptake in PET by bladder hernia simulating inguinal metastasis. Yonsei Med J (2007) 0.75
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science (2003) 3.19
Multicenter trial of high-speed versus conventional single-photon emission computed tomography imaging: quantitative results of myocardial perfusion and left ventricular function. J Am Coll Cardiol (2010) 1.93
The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med (2012) 1.84
The tinnitus functional index: development of a new clinical measure for chronic, intrusive tinnitus. Ear Hear (2012) 1.61
PET myocardial glucose metabolism and perfusion imaging: Part 1-Guidelines for data acquisition and patient preparation. J Nucl Cardiol (2003) 1.39
Methodological aspects of clinical trials in tinnitus: a proposal for an international standard. J Psychosom Res (2012) 1.19
Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. J Nucl Med (2004) 1.17
Electrical stimulation for intraoperative evaluation of thoracic pedicle screw placement. Spine (Phila Pa 1976) (2003) 1.11
Sestamibi scanning and minimally invasive radioguided parathyroidectomy without intraoperative parathyroid hormone measurement. Ann Surg (2003) 1.08
Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. Semin Nucl Med (2009) 1.05
Cerebral lesions incidentally detected on 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography images of patients evaluated for body malignancies. Mol Imaging Biol (2002) 1.02
CT-based attenuation correction versus prone imaging to decrease equivocal interpretations of rest/stress Tc-99m tetrofosmin SPECT MPI. J Nucl Cardiol (2007) 0.97
Hearing aids as an adjunct to counseling: tinnitus patients who choose amplification do better than those that don't. Int J Audiol (2010) 0.96
Update of PET and PET/CT for hepatobiliary and pancreatic malignancies. HPB (Oxford) (2005) 0.90
2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography uptake in a giant adrenal myelolipoma. Mol Imaging Biol (2002) 0.85
Unsuspected skeletal sarcoidosis mimicking metastatic disease on FDG positron emission tomography and bone scintigraphy. Clin Nucl Med (2003) 0.84
CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J Biol Chem (2003) 0.84
PET and PET/CT for pancreatic malignancies. Surg Oncol Clin N Am (2010) 0.83
[18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report. Am Surg (2003) 0.81
Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease. J Med Chem (2014) 0.80
Serendipitous detection of Cushing's disease by FDG positron emission tomography and a review of the literature. Clin Nucl Med (2002) 0.80
Benzimidazolone p38 inhibitors. Bioorg Med Chem Lett (2004) 0.80
FDG PET and PET/CT for colorectal cancer. Methods Mol Biol (2011) 0.78
Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. Clin Nucl Med (2004) 0.78
Incremental value of fusion imaging with integrated PET-CT in oncology. Clin Nucl Med (2005) 0.78
Potent small molecule CCR1 antagonists. Bioorg Med Chem Lett (2004) 0.78
Metabolic imaging with FDG: a primer. Cancer J (2004) 0.77
The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template. Bioorg Med Chem Lett (2004) 0.77
Initial multicentre experience of high-speed myocardial perfusion imaging: comparison between high-speed and conventional single-photon emission computed tomography with angiographic validation. Eur J Nucl Med Mol Imaging (2013) 0.76
Calcium channel blockers: a potential cause of false-positive captopril renography. Clin Nucl Med (2003) 0.76
Positron emission tomography/computed tomography of a rare xanthogranulomatous process: Erdheim-Chester disease. Mol Imaging Biol (2004) 0.75
Identification of an infected left ventricular assist device after cardiac transplant by indium-111 WBC scintigraphy. Clin Nucl Med (2005) 0.75
A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one. J Med Chem (2003) 0.75
NanoStore: a concept for logistical improvements of compound handling in high-throughput screening. J Biomol Screen (2005) 0.75
2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. Mol Imaging Biol (2002) 0.75